Ling WU
Ling graduated his Bachelor‘s and Master‘s study from Peking University, where he has a master‘s
research experience of engineering therapeutic proteins. He then became a visiting scholar in
Harvard medical school studying the protein crystallography before he starts his current PhD study
of cancer immunology in the National University of Singapore (NUS). His PhD research project is
generating novel chimeric antigen receptor T cell (CAR-T) technology though CAR signaling
modulation which makes CAR-T safer and more persistent in vivo. The technology has been
patented and under commercialization. Ling is passionate about biotechnology and business
development. Before Ling joins BCS as the consulting lead, he was also part-timing in Mybiogate
Inc. as the associate consultant, where he has finished multiple market analysis and access
projects, such as global CAR-T immunotherapy, anti-PD-1 (L1) antibody combination therapy, and
gene therapy. Through these experiences, Ling has familiarized himself with technology due
diligence, market landscape analysis and access strategy, biotech entrepreneurship, patenting, and
business development. In BCS, he hopes to contribute to the regional biotech- and
pharma-industry and to the allyship strengthening in the community. Outside of work, Ling is a
semi-professional tennis and basketball player and loves to explore nature.
Biotech Connection Singapore
Biotech Connection Singapore (BCS) is part of an international network of non-profit organizations, that aims to promote the transfer of ideas from theory to real world applications by providing a platform for fostering interaction between academia, industry and businesses.
